Treatment interruption after one year of triple nucleoside analogue therapy for primary HIV infection.
Girard
P M
PM
Service des Maladies Infectieuses et Tropicales, H pital Rothschild, Paris, France.
Schneider
V
V
Dehée
A
A
Mariot
P
P
Jacomet
C
C
Delphin
N
N
Damond
F
F
Carcelain
G
G
Autran
B
B
Saimot
A G
AG
Nicolas
J C
JC
Rozenbaum
W
W
D019380:Anti-HIV Agents / Q000627:therapeutic use*; D018791:CD4 Lymphocyte Count; D016049:Didanosine / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D015658:HIV Infections / Q000188:drug therapy* / Q000276:immunology / Q000821:virology; D054303:HIV Reverse Transcriptase / Q000235:genetics; D015497:HIV-1 / Q000235:genetics; D006801:Humans; D019259:Lamivudine / Q000627:therapeutic use*; D018894:Reverse Transcriptase Inhibitors / Q000627:therapeutic use*; D013997:Time Factors; D019562:Viral Load; D015215:Zidovudine / Q000627:therapeutic use*
D019380:Anti-HIV Agents; D018894:Reverse Transcriptase Inhibitors; D019259:Lamivudine; D015215:Zidovudine; D054303:HIV Reverse Transcriptase; D016049:Didanosine